530 HERMAN O. WEST DRIVE, EXTON, PA
Reports Second-Quarter 2026 Results
West Pharmaceutical Services Enters Material Agreements with Daikyo
Investor Presentation
Amended material disclosure
Is committed to providing timely and transparent communication to all stakeholders regarding the recent cyberattack on its network systems.
West Pharmaceutical Services Elects Eleven Directors at Annual Meeting
Reports First-Quarter 2026 Results – Strong Start to the Year and Raising Full Year Revenue and EPS guidance
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Additional Proxy Soliciting Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Specialized Disclosure Report
S-8 POS